Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07102615

Intracervical Vasopressin

This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus.

The main goal of the study is :

• To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC.

Participants will:

• would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Retained Products of Conception

Age range

18 year–51 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

The OB/GYN Center

Greenville, South Carolina, 29605, United States

Location status: Recruiting

Location contact

Erica Lowing, MD

CONTACT

[email protected]

864-455-1600

About this study

This double-blinded randomized control trial is designed to evaluate if intraoperative injection of intracervical vasopressin into the cervix will allow for completion of hysteroscopic removal of retained products of conception. This will be measured by surgical completion comparing patients who received intracervical vasopressin and those receiving placebo. Surgical completion is defined by completing the procedure without having to convert to suction of tissue due to bleeding or poor visualization. Secondary outcome measures include intraoperative bleeding, operative time, fluid deficit, and deficit volume.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women
  • Aged 18-51
  • Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion

Exclusion criteria

  • Hemodynamic instability
  • Active hemorrhage- soaking pad/hour
  • Allergy to vasopressin
  • Concern for intrauterine arteriovenous malformation
  • Inability to consent

Treatment and study plan

Intracervical injection of Vasopressin

Drug

Intracervical injection of Vasopressin

Intracervical Injection of saline

Drug

Intracervical Injection of saline

Primary outcomes

  1. Completion of procedure hysteroscopically

    Time frame: from start of procedure to end of procedure

    There is complete removal of RPOC hysteroscopically by the end of the procedure.

Secondary outcomes

  1. Intraoperative Bleeding

    Time frame: from start of procedure to end of procedure

    calculated by dividing the number of red blood cells per milliliter of outflow distention fluid by the number of red blood cells per milliliter of the woman's blood immediately before the procedure and multiplying this quotient by the total amount of outflow fluid collected

  2. Operative time

    Time frame: time from insertion of hysteroscope to procedure completion

    time from insertion of hysteroscope to procedure completion

  3. fluid deficit volume

    Time frame: from start of procedure to end of procedure

    The difference between the total volume of distension fluid infusion into the uterine cavity during the hysteroscopy and the volume of fluid recovered from the outflow.

Study contacts

Contact information is provided by the study sponsor or research team.

Patti Parker, BSN

CONTACT

[email protected]

864-455-1510

Paul Miller, MD

CONTACT

[email protected]

894-455-1600

Sponsors and collaborators

Lead sponsor

Prisma Health-Upstate

Other

Registry information

Official study title

Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 4, 2025
Registry last updated
Nov 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.